Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4973063 | 0.82 | ALDH1A1 (0.36) | SMN1; SMN2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL8373524 | 0.81 | CHRNB2 (0.37) | SMN1; SMN2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL28033377 | 0.81 | CHRNB2 (0.37) | SMN1; SMN2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL25337703 | 0.78 | CA1 (0.46) | SMN1; SMN2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL8585524 | 0.76 | SMN1; SMN2 (0.33) | SMN1; SMN2ALDH1A1TSHRMAPK1CASP7 | |
| SCHEMBL8885327 | 0.76 | PGR (0.42) | SMN1; SMN2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL466242 | 0.76 | MEN1 (0.39) | SMN1; SMN2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL4979486 | 0.76 | MEN1 (0.39) | SMN1; SMN2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL8582715 | 0.75 | CHRNB2 (0.33) | SMN1; SMN2ALDH1A1TSHRMAPK1CASP7 | |
| SCHEMBL16964691 | 0.75 | ZDHHC7 (0.49) | MEN1KMT2AMAPK1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058543-A1 | Process for making chiral 1,4-disubstituted piperazines | ZELDIS JOSEPH | 2008-03-06 | — | — | US | claimed |
| US-20050228181-A1 | Process for making chiral 1,4-disubstituted piperazines | WYETH (US) | 2005-10-13 | — | — | US | claimed |
| EP-1483256-A2 | PROCESS FOR MAKING CHIRAL 1,4-DISUBSTITUTED PIPERAZINES | Wyeth (US) | 2004-12-08 | — | — | EP | claimed |
| US-20030208075-A1 | Process for making chiral 1,4-disubstituted piperazines | WYETH | 2003-11-06 | — | — | US | claimed |
| WO-2003078420-A2 | PROCESS FOR MAKING CHIRAL 1,4-DISUBSTITUTED PIPERAZINES | WYETH (US) | 2003-09-25 | — | — | WO | claimed |
| US-20080058543-A1 | Process for making chiral 1,4-disubstituted piperazines | ZELDIS JOSEPH | 2008-03-06 | — | — | US | disclosed |
| US-7256289-B2 | Process for making chiral 1,4-disubstituted piperazines | WYETH (US) | 2007-08-14 | — | — | US | disclosed |
| US-7019137-B2 | Process for making chiral 1,4-disubstituted piperazines | WYETH (US) | 2006-03-28 | — | — | US | disclosed |
| US-20050228181-A1 | Process for making chiral 1,4-disubstituted piperazines | WYETH (US) | 2005-10-13 | — | — | US | disclosed |
| EP-1483256-A2 | PROCESS FOR MAKING CHIRAL 1,4-DISUBSTITUTED PIPERAZINES | Wyeth (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20030208075-A1 | Process for making chiral 1,4-disubstituted piperazines | WYETH | 2003-11-06 | — | — | US | disclosed |
| WO-2003078420-A2 | PROCESS FOR MAKING CHIRAL 1,4-DISUBSTITUTED PIPERAZINES | WYETH (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058543-A1 | Process for making chiral 1,4-disubstituted piperazines | HTR5A, HTR1A, HTR1D | SMN1; SMN2 1710/4885MEN1 2420/4885KMT2A 1357/4885 |
| US-20030208075-A1 | Process for making chiral 1,4-disubstituted piperazines | HTR1D, HTR1A, HTR5A | SMN1; SMN2 1526/4885MEN1 1950/4885KMT2A 1586/4885 |
| US-20050228181-A1 | Process for making chiral 1,4-disubstituted piperazines | HTR5A, HTR1A, HTR1D | SMN1; SMN2 1710/4885MEN1 2420/4885KMT2A 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.